Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Running The Gauntlet: Takeaways From The First Round Of HHS Hearings In 2019

Executive Summary

Release of the White House budget proposal kicked off the first round of hearings on HHS with a new Democratic majority in the House and a new HHS budget czar in the Senate. HHS Secretary Azar did his best to set a constructive tone for advancing drug pricing policies – and maintaining his own position – in the year to come.  

You may also be interested in...



Part D Premiums ‘Won’t Go Up’ With HHS Rebate Proposal, Azar Maintains

US HHS secretary tells Senate Finance Committee he believes pharmacy benefit managers will effectively keep drug costs down in Medicare Part D, even without rebates.

CMS Part D Protected Class Restrictions Drawing Bipartisan Concerns In Congress

Congressional objections to proposal join opposition by patient and physician groups.

New Acting US FDA Commissioner Shares Agency's Clinical Trial Reform Message

Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs.

Related Content

Topics

UsernamePublicRestriction

Register

PS124964

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel